Hub : Traits :

Medication for cholesterol, blood pressure or diabetes

131 significantly associated models · 35 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	5988926	7460433	2	1	1.8e-07	4.4e-07	3.8e-01	97	DNAJC11
2	1	11060075	12600396	2	1	6.9e-11	9.6e-11	1.8e-02	86	CLCN6
3	1	109098737	110733794	4	1	3.9e-20	3.2e-20	1.0e+00	100	PSRC1
4	2	20529948	21958745	1	1	4.7e-09	1.2e-09	1.7e-02	84	APOB
5	3	26720690	28211713	1	1	2.7e-07	8.8e-08	5.2e-02	87	SLC4A7
6	7	99122437	100516003	1	1	9.7e-08	2.1e-06	9.7e-01	100	PVRIG
7	11	99859184	101559718	2	1	5.5e-14	1.3e-13	1.8e-01	97	TMEM133
8	11	110721187	112287801	3	1	7.3e-10	6.1e-10	1.0e+00	100	SIK2
9	11	115953897	117745003	3	3	4.7e-14	4.1e-15	8.5e-01	100	BUD13 PAFAH1B2 ZNF259
10	12	89286081	90799212	1	1	1.1e-07	3.1e-09	8.3e-03	80	ATP2B1
11	12	111154626	112582540	1	1	2.0e-07	1.2e-10	5.4e-05	61	SH2B3
12	15	74042497	75724703	2	1	4.6e-08	4.5e-08	2.3e-01	95	CSK
13	15	90712555	92135418	2	1	8.3e-19	1.1e-15	6.7e-01	100	FES
14	17	60858059	62279811	2	1	1.3e-10	9.7e-10	1.0e+00	100	ACE
15	19	10793749	12191233	1	1	2.9e-07	1.8e-14	3.0e-09	40	EPOR
16	20	30083621	31469577	1	1	9.0e-08	7.3e-06	1.9e-01	92	TSPY26P
17	20	57525478	58079512	1	1	3.4e-09	1.0e-12	2.5e-05	65	ZNF831
18	20	61989111	62912463	4	1	1.2e-10	5.5e-09	3.2e-01	97	RGS19
19	21	44711272	45327770	1	1	1.1e-07	1.3e-07	8.5e-02	89	HSF2BP

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	50.33	8	6	13.3	-0.60	1.2e-01	APOB BUD13 CSK EPOR PAFAH1B2 PSRC1 SH2B3 ZNF259
Triglycerides	40.96	4	4	8.9	-0.58	4.2e-01	APOB BUD13 PAFAH1B2 ZNF259
High cholesterol (Self-reported)	36.57	9	8	17.8	-0.29	4.5e-01	APOB BUD13 CLCN6 EPOR PAFAH1B2 PSRC1 RGS19 TMEM133 ZNF259
Medication: Cholesterol lowering	27.04	16	9	20.0	-0.90	2.6e-06	APOB BUD13 CLCN6 CSK DNAJC11 EPOR FES PAFAH1B2 PSRC1 PVRIG RGS19 SIK2 TMEM133 TSPY26P ZNF259 ZNF831
Cardiovascular Disease	23.53	21	20	44.4	-0.96	5.4e-12	ACE APOB ATP2B1 BUD13 CLCN6 CSK DNAJC11 EPOR FES HSF2BP PAFAH1B2 PSRC1 PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P ZNF259 ZNF831
Systolic Blood Pressure	21.70	16	13	28.9	-0.89	4.8e-06	ACE ATP2B1 CLCN6 CSK DNAJC11 EPOR FES HSF2BP PAFAH1B2 RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P ZNF831
Medication: Simvastatin	19.97	13	6	13.3	-0.90	2.4e-05	APOB BUD13 DNAJC11 EPOR FES PAFAH1B2 PSRC1 PVRIG RGS19 SIK2 TMEM133 ZNF259 ZNF831
Vascular/heart problems diagnosed by doctor	19.50	15	12	26.7	0.97	1.2e-09	ACE ATP2B1 CLCN6 CSK DNAJC11 FES HSF2BP PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P ZNF831
High blood pressure	18.85	15	13	28.9	-0.97	2.2e-09	ACE ATP2B1 CLCN6 CSK DNAJC11 FES HSF2BP PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P ZNF831
Hypertension (Self-reported)	18.85	15	13	28.9	-0.97	1.9e-09	ACE ATP2B1 CLCN6 CSK DNAJC11 FES HSF2BP PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P ZNF831
Medication: Blood pressure	18.64	15	13	28.9	-0.98	4.2e-11	ACE ATP2B1 CLCN6 CSK DNAJC11 FES HSF2BP PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P ZNF831
Cholesterol lowering medication	18.17	7	7	15.6	-0.61	1.4e-01	APOB BUD13 EPOR PAFAH1B2 PSRC1 RGS19 ZNF259
Medication: Atorvastatin	15.57	7	6	13.3	-0.81	2.6e-02	APOB BUD13 EPOR PAFAH1B2 PSRC1 RGS19 ZNF259
Systolic blood pressure, automated reading	14.92	11	9	20.0	-0.95	1.0e-05	ATP2B1 CLCN6 CSK DNAJC11 FES RGS19 SH2B3 SIK2 SLC4A7 TMEM133 ZNF831
Diastolic blood pressure, automated reading	13.83	11	7	15.6	-0.92	6.5e-05	ATP2B1 CLCN6 CSK FES PVRIG RGS19 SH2B3 SIK2 TMEM133 TSPY26P ZNF831
Medication: Blood pressure	13.06	11	8	17.8	-0.98	3.5e-07	ACE ATP2B1 CLCN6 CSK FES RGS19 SH2B3 SIK2 SLC4A7 TMEM133 ZNF831
HDL Cholesterol	10.63	4	2	4.4	-0.35	6.5e-01	APOB BUD13 PSRC1 ZNF259
Blood Eosinophil Count	10.37	10	5	11.1	-0.65	4.3e-02	BUD13 CLCN6 EPOR HSF2BP PAFAH1B2 SH2B3 SIK2 TSPY26P ZNF259 ZNF831
High blood pressure (mother)	8.69	7	1	2.2	-0.96	7.0e-04	CLCN6 CSK DNAJC11 FES SLC4A7 TMEM133 ZNF831
Medication: Atenolol	8.57	5	2	4.4	-0.97	7.5e-03	CLCN6 FES PSRC1 SH2B3 TMEM133
Medication for cholesterol	8.42	10	2	4.4	0.97	3.2e-06	ACE CLCN6 FES PAFAH1B2 PSRC1 RGS19 SH2B3 TMEM133 TSPY26P ZNF831
Medication: Aspirin	8.37	6	2	4.4	-1.00	3.0e-06	EPOR FES PSRC1 RGS19 SH2B3 SIK2
Medication: Aspirin	8.10	6	2	4.4	-1.00	5.0e-06	EPOR FES PSRC1 RGS19 SH2B3 SIK2
Illnesses of father: Heart disease	7.86	6	2	4.4	-1.00	1.6e-05	EPOR FES PSRC1 RGS19 SH2B3 SIK2
Medication: Amlodipine	7.78	8	3	6.7	-0.85	8.0e-03	ACE ATP2B1 CLCN6 FES SLC4A7 TMEM133 TSPY26P ZNF831
Angina (self-reported)	7.65	4	2	4.4	-0.79	2.1e-01	FES PSRC1 RGS19 TMEM133
Medication: Bendroflumethiazide	7.61	9	4	8.9	-0.98	2.8e-06	ATP2B1 CLCN6 CSK FES SH2B3 SIK2 SLC4A7 TMEM133 ZNF831
Angina	7.44	4	2	4.4	-0.80	2.0e-01	FES PSRC1 RGS19 TMEM133
High blood pressure (siblings)	7.34	6	2	4.4	-0.99	7.6e-05	CLCN6 FES HSF2BP SH2B3 SLC4A7 TMEM133
Medication: Ramipril	7.27	3	2	4.4	0.00	1.0e+00	CSK FES TMEM133
Illnesses of father: High blood pressure	6.97	6	1	2.2	-0.97	1.0e-03	ACE ATP2B1 CLCN6 FES SH2B3 TMEM133
Coronary Artery Disease (CAD)	6.94	5	2	4.4	-0.96	1.1e-02	BUD13 EPOR PSRC1 SH2B3 ZNF259
Number of treatments/medications taken	6.66	8	4	8.9	-0.95	3.1e-04	ACE FES PSRC1 SH2B3 SLC4A7 TMEM133 TSPY26P ZNF831
Number of self-reported non-cancer illnesses	6.61	5	2	4.4	-0.96	9.3e-03	CLCN6 RGS19 SH2B3 TMEM133 ZNF831
Medication: Lisinopril	6.40	6	0	0.0	-0.97	1.3e-03	CSK FES SH2B3 SLC4A7 TMEM133 ZNF831
Birth weight of first child	6.18	5	3	6.7	0.98	2.4e-03	CLCN6 CSK FES RGS19 SH2B3
Hypothyroidism (self reported)	6.04	1	1	2.2	0.00	1.0e+00	SH2B3
Illnesses of siblings	5.96	5	1	2.2	0.99	8.2e-04	CLCN6 FES SH2B3 TMEM133 TSPY26P
Heart attack	5.81	4	2	4.4	-1.00	1.7e-03	FES PSRC1 SH2B3 ZNF831
Heart attack/myocardial infarction (self-reported)	5.69	4	2	4.4	-1.00	3.4e-04	FES PSRC1 SH2B3 ZNF831
Illnesses of mother	5.37	2	1	2.2	0.00	1.0e+00	FES TMEM133
Hypothyroidism/myxoedema (self-reported)	5.32	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Levothyroxine sodium	5.05	1	1	2.2	0.00	1.0e+00	SH2B3
Illnesses of father: None of the above (group 1)	4.89	2	1	2.2	0.00	1.0e+00	FES SH2B3
Breast Cancer	4.87	6	1	2.2	-0.52	3.0e-01	CSK FES HSF2BP RGS19 SIK2 SLC4A7
Heart disease (siblings)	4.85	3	0	0.0	0.00	1.0e+00	FES PVRIG ZNF259
Blood White Count	4.73	6	2	4.4	-0.97	1.2e-03	ACE FES PAFAH1B2 SH2B3 TMEM133 TSPY26P
Father's age at death	4.64	4	2	4.4	0.99	1.4e-02	CSK FES PSRC1 SH2B3
Birth weight	3.54	3	3	6.7	0.00	1.0e+00	FES SH2B3 SIK2
Allergy	3.03	3	1	2.2	0.00	1.0e+00	CLCN6 FES SIK2
Hayfever, allergic rhinitis or eczema	3.01	3	1	2.2	0.00	1.0e+00	CSK HSF2BP SIK2
Mean time to correctly identify matches	2.96	2	1	2.2	0.00	1.0e+00	FES SH2B3
Bipolar Disorder or Schizophrenia	2.89	3	1	2.2	0.00	1.0e+00	CLCN6 CSK FES
Allergy or Eczema	2.81	6	1	2.2	0.74	9.6e-02	CLCN6 CSK FES HSF2BP SH2B3 SIK2
Breast cancer (self-reported)	2.80	1	0	0.0	0.00	1.0e+00	SLC4A7
Blood Platelet Count	2.76	7	5	11.1	0.41	3.7e-01	BUD13 CSK PAFAH1B2 SH2B3 SIK2 SLC4A7 ZNF259
Back pain experienced in last month	2.69	2	0	0.0	0.00	1.0e+00	APOB ATP2B1
Taking other prescription medications	2.63	1	1	2.2	0.00	1.0e+00	SH2B3
Lung FEV1/FVC ratio	2.61	6	5	11.1	-0.05	9.2e-01	ATP2B1 DNAJC11 PSRC1 PVRIG TMEM133 TSPY26P
Blood Red Count	2.54	7	4	8.9	-0.51	2.4e-01	CLCN6 CSK FES HSF2BP PVRIG SH2B3 TSPY26P
Schizophrenia (2018)	2.52	1	1	2.2	0.00	1.0e+00	FES
Pulse wave peak to peak time	2.52	1	0	0.0	0.00	1.0e+00	FES
Primary Biliary Cirrhosis	2.48	2	1	2.2	0.00	1.0e+00	EPOR SH2B3
Pulse wave Arterial Stiffness index	2.47	2	0	0.0	0.00	1.0e+00	CLCN6 FES
Rheumatoid Arthritis	2.43	2	0	0.0	0.00	1.0e+00	RGS19 SH2B3
Type 2 Diabetes (T2D) (2018)	2.42	2	0	0.0	0.00	1.0e+00	ACE SH2B3
Hayfever/allergic rhinitis (self-reported)	2.42	1	0	0.0	0.00	1.0e+00	HSF2BP
Bipolar Disorder (2018)	2.40	1	0	0.0	0.00	1.0e+00	CSK
Chronic bronchitis/emphysema (mother)	2.39	1	0	0.0	0.00	1.0e+00	SIK2
Diabetes diagnosed by doctor	2.39	1	0	0.0	0.00	1.0e+00	ACE
Gout (self-reported)	2.36	1	0	0.0	0.00	1.0e+00	SH2B3
Had other major operations	2.18	1	0	0.0	0.00	1.0e+00	RGS19
Alzheimer’s Disease (including proxy)	2.12	2	1	2.2	0.00	1.0e+00	ACE PVRIG
Schizophrenia (2014)	2.12	1	1	2.2	0.00	1.0e+00	FES
Osteoarthritis (self-reported)	2.11	2	0	0.0	0.00	1.0e+00	CSK SIK2
Reaction Time	2.09	1	1	2.2	0.00	1.0e+00	SH2B3
Diabetes (self-reported)	2.08	1	0	0.0	0.00	1.0e+00	ACE
Pulse rate, automated reading	2.08	3	1	2.2	0.00	1.0e+00	APOB PVRIG SIK2
Asthma	2.01	1	1	2.2	0.00	1.0e+00	SIK2
Hearing difficulty/problems with background noise	1.98	1	0	0.0	0.00	1.0e+00	CSK
Pain experienced in last month	1.96	1	0	0.0	0.00	1.0e+00	SH2B3
Ever smoked	1.94	2	0	0.0	0.00	1.0e+00	FES SH2B3
Overall health rating	1.91	2	0	0.0	0.00	1.0e+00	TSPY26P ZNF831
Asthma (self-reported)	1.85	1	1	2.2	0.00	1.0e+00	SIK2
Supplements: Glucosamine	1.84	1	0	0.0	0.00	1.0e+00	CSK
Past tobacco smoking	1.84	1	0	0.0	0.00	1.0e+00	SH2B3
Ever had bowel cancer screening	1.84	1	0	0.0	0.00	1.0e+00	SIK2
Lupus	1.82	1	0	0.0	0.00	1.0e+00	CSK
Wheeze or whistling in the chest in last year	1.80	1	0	0.0	0.00	1.0e+00	SIK2
Deep venous thrombosis (DVT) (self-reported)	1.80	1	0	0.0	0.00	1.0e+00	SH2B3
Other serious medical condition/disability diagnosed by doctor	1.76	1	0	0.0	0.00	1.0e+00	CSK
Trunk fat-free mass	1.75	5	3	6.7	0.76	1.3e-01	EPOR PSRC1 SH2B3 SLC4A7 TMEM133
Ever taken oral contraceptive pill	1.75	1	0	0.0	0.00	1.0e+00	TSPY26P
Fed-up feelings	1.74	1	1	2.2	0.00	1.0e+00	SH2B3
Trunk predicted mass	1.74	5	3	6.7	0.77	1.3e-01	EPOR PSRC1 SH2B3 SLC4A7 TMEM133
Blood clot in the leg (DVT)	1.74	1	0	0.0	0.00	1.0e+00	SH2B3
Diabetes (mother)	1.71	1	0	0.0	0.00	1.0e+00	RGS19
Pulse rate	1.71	1	0	0.0	0.00	1.0e+00	PVRIG
Arm predicted mass (left)	1.71	5	1	2.2	0.69	2.0e-01	EPOR PSRC1 SH2B3 SLC4A7 TSPY26P
Risk taking	1.70	1	0	0.0	0.00	1.0e+00	FES
Medication for pain relief, constipation, heartburn	1.68	1	0	0.0	0.00	1.0e+00	ACE
Smoking status: Previous	1.67	1	0	0.0	0.00	1.0e+00	SH2B3
Leg fat percentage (right)	1.66	3	1	2.2	0.00	1.0e+00	CLCN6 DNAJC11 TSPY26P
Arm fat-free mass (left)	1.66	5	1	2.2	0.69	2.0e-01	EPOR PSRC1 SH2B3 SLC4A7 TSPY26P
Irritable Bowel Disease (IBD)	1.63	1	0	0.0	0.00	1.0e+00	RGS19
Leg fat percentage (left)	1.62	3	1	2.2	0.00	1.0e+00	CLCN6 DNAJC11 TSPY26P
Ulcerative Colitis (UC)	1.61	1	0	0.0	0.00	1.0e+00	RGS19
Number of incorrect matches in round	1.60	1	0	0.0	0.00	1.0e+00	FES
Headache pain in last month	1.60	1	0	0.0	0.00	1.0e+00	FES
Medication: Allopurinol	1.60	1	0	0.0	0.00	1.0e+00	SH2B3
Whole body fat-free mass	1.59	5	2	4.4	0.77	1.3e-01	EPOR PSRC1 SH2B3 SLC4A7 TMEM133
Sensitivity / hurt feelings	1.58	1	1	2.2	0.00	1.0e+00	FES
Arm fat-free mass (right)	1.57	5	1	2.2	0.68	2.1e-01	EPOR PSRC1 SH2B3 SLC4A7 TSPY26P
Whole body water mass	1.57	6	1	2.2	0.79	6.1e-02	EPOR FES PSRC1 SH2B3 SLC4A7 TMEM133
Smoking Status	1.56	1	0	0.0	0.00	1.0e+00	FES
Arm predicted mass (right)	1.55	5	1	2.2	0.68	2.1e-01	EPOR PSRC1 SH2B3 SLC4A7 TSPY26P
Waist Hip Ratio (WHR)	1.49	2	1	2.2	0.00	1.0e+00	RGS19 SIK2
Had menopause	1.49	1	0	0.0	0.00	1.0e+00	DNAJC11
Mouth/teeth dental problems: Mouth ulcers	1.48	2	0	0.0	0.00	1.0e+00	SH2B3 SLC4A7
Basal metabolic rate	1.48	3	1	2.2	0.00	1.0e+00	EPOR PSRC1 SH2B3
Ulcerative Colitis	1.46	1	0	0.0	0.00	1.0e+00	PAFAH1B2
Loneliness, isolation	1.44	1	0	0.0	0.00	1.0e+00	SH2B3
Waist circumference	1.43	2	1	2.2	0.00	1.0e+00	CSK DNAJC11
Leg predicted mass (right)	1.38	5	0	0.0	0.96	1.1e-02	EPOR FES PSRC1 SH2B3 TMEM133
Respiratory disease	1.37	2	0	0.0	0.00	1.0e+00	FES SIK2
Medication: Ibuprofen (e.g. Nurofen)	1.37	1	0	0.0	0.00	1.0e+00	CSK
Leg fat-free mass (right)	1.37	5	0	0.0	0.96	1.0e-02	EPOR FES PSRC1 SH2B3 TMEM133
Body fat percentage	1.36	2	0	0.0	0.00	1.0e+00	DNAJC11 SLC4A7
Average weekly red wine intake	1.36	1	0	0.0	0.00	1.0e+00	CSK
Medication: Lansoprazole	1.33	1	0	0.0	0.00	1.0e+00	SH2B3
Leg fat mass (left)	1.32	2	1	2.2	0.00	1.0e+00	DNAJC11 TSPY26P
Leg fat-free mass (left)	1.31	4	0	0.0	0.97	3.5e-02	EPOR FES SH2B3 TMEM133
Leg predicted mass (left)	1.31	4	0	0.0	0.96	3.9e-02	EPOR FES SH2B3 TMEM133
Leg fat mass (right)	1.31	2	1	2.2	0.00	1.0e+00	DNAJC11 TSPY26P
Hip circumference	1.30	3	1	2.2	0.00	1.0e+00	CLCN6 DNAJC11 SH2B3
Forced expiratory volume in 1-second (FEV1)	1.28	3	0	0.0	0.00	1.0e+00	EPOR TMEM133 TSPY26P
Forced expiratory volume in 1-second (FEV1), Best measure	1.28	3	0	0.0	0.00	1.0e+00	EPOR TMEM133 TSPY26P
Impedance of arm (left)	1.27	3	0	0.0	0.00	1.0e+00	SH2B3 SLC4A7 TSPY26P
Impedance of whole body	1.26	4	0	0.0	0.16	8.4e-01	RGS19 SIK2 SLC4A7 TMEM133
Heel T-Score	1.25	4	2	4.4	-0.65	3.5e-01	DNAJC11 PSRC1 SLC4A7 TMEM133
Impedance of leg (right)	1.25	4	1	2.2	-0.62	3.8e-01	FES RGS19 SIK2 TMEM133
Impedance of leg (left)	1.23	4	1	2.2	-0.70	3.0e-01	FES RGS19 SIK2 TMEM133
Weight	1.23	4	0	0.0	0.03	9.7e-01	DNAJC11 EPOR SH2B3 TSPY26P
Impedance of arm (right)	1.22	3	0	0.0	0.00	1.0e+00	SH2B3 SLC4A7 TSPY26P
Arm fat percentage (right)	1.21	1	0	0.0	0.00	1.0e+00	DNAJC11
Trunk fat percentage	1.20	1	0	0.0	0.00	1.0e+00	DNAJC11
Heel bone mineral density (BMD) T-score, automated (left)	1.18	2	0	0.0	0.00	1.0e+00	DNAJC11 TMEM133
Alcohol usually taken with meals	1.17	1	0	0.0	0.00	1.0e+00	FES
Whole body fat mass	1.16	2	0	0.0	0.00	1.0e+00	DNAJC11 TSPY26P
Arm fat mass (right)	1.14	1	0	0.0	0.00	1.0e+00	DNAJC11
Arm fat percentage (left)	1.14	1	0	0.0	0.00	1.0e+00	DNAJC11
Handedness (chirality/laterality): Left-handed	1.14	1	0	0.0	0.00	1.0e+00	FES
Age when periods started (menarche)	1.13	1	0	0.0	0.00	1.0e+00	PVRIG
Hand grip strength (left)	1.11	1	0	0.0	0.00	1.0e+00	FES
Trunk fat mass	1.11	1	0	0.0	0.00	1.0e+00	DNAJC11
Breastfed as a baby	1.11	1	0	0.0	0.00	1.0e+00	FES
Comparative body size at age 10	1.10	1	0	0.0	0.00	1.0e+00	DNAJC11
Comparative height size at age 10	1.10	3	1	2.2	0.00	1.0e+00	FES PSRC1 SH2B3
Arm fat mass (left)	1.10	2	0	0.0	0.00	1.0e+00	DNAJC11 TSPY26P
Mouth/teeth dental problems: Dentures	1.09	1	0	0.0	0.00	1.0e+00	HSF2BP
BMI	1.07	3	2	4.4	0.00	1.0e+00	CSK DNAJC11 TSPY26P
Nervous feelings	1.06	1	0	0.0	0.00	1.0e+00	TSPY26P
Heel bone mineral density (BMD) T-score, automated (right)	1.05	2	0	0.0	0.00	1.0e+00	DNAJC11 TMEM133
Depressed Affect (Nagel 2018)	1.04	1	0	0.0	0.00	1.0e+00	SH2B3
Body mass index (BMI)	1.01	2	0	0.0	0.00	1.0e+00	DNAJC11 TSPY26P
Lung FVC	1.00	4	0	0.0	-0.05	9.5e-01	CLCN6 PVRIG RGS19 SH2B3
Qualifications: A levels/AS levels or equivalent	0.97	1	0	0.0	0.00	1.0e+00	CSK
Qualifications: College or University degree	0.96	1	0	0.0	0.00	1.0e+00	BUD13
Worrier / anxious feelings	0.93	1	0	0.0	0.00	1.0e+00	TSPY26P
Height	0.91	9	7	15.6	0.61	8.0e-02	ACE EPOR FES PSRC1 SH2B3 SLC4A7 TMEM133 ZNF259 ZNF831
Sitting height	0.87	4	0	0.0	-0.25	7.5e-01	FES HSF2BP SLC4A7 ZNF831
Forced vital capacity (FVC)	0.86	2	0	0.0	0.00	1.0e+00	EPOR TMEM133
Hair Pigment	0.85	8	5	11.1	0.40	3.3e-01	ATP2B1 EPOR FES RGS19 SH2B3 TMEM133 TSPY26P ZNF831
Standing height	0.84	5	3	6.7	0.54	3.5e-01	EPOR PSRC1 SH2B3 SLC4A7 ZNF831
Forced vital capacity (FVC), Best measure	0.84	1	0	0.0	0.00	1.0e+00	EPOR
Hair/balding pattern: Pattern 4	0.82	1	0	0.0	0.00	1.0e+00	FES
Exposure to tobacco smoke outside home	0.78	1	0	0.0	0.00	1.0e+00	SH2B3
Tanning	0.61	6	1	2.2	-0.63	1.8e-01	CLCN6 CSK EPOR SH2B3 TMEM133 TSPY26P

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adrenal Gland	2	0.137	1.8
GTEx	Brain Cortex	0	0.000	1.8
GTEx	Lung	2	0.070	1.8
GTEx	Muscle Skeletal	3	0.104	1.8
GTEx	Stomach	2	0.138	1.8
GTEx	Vagina	1	0.157	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.238	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.8
GTEx	Adipose Subcutaneous	2	0.057	1.7
GTEx	Adipose Visceral Omentum	1	0.049	1.7
GTEx	Artery Aorta	5	0.168	1.7
GTEx	Artery Tibial	6	0.160	1.7
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.7
GTEx	Brain Cerebellum	1	0.050	1.7
GTEx	Brain Frontal Cortex BA9	0	0.000	1.7
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.7
GTEx	Breast Mammary Tissue	0	0.000	1.7
GTEx	Cells Transformed fibroblasts	4	0.095	1.7
GTEx	Colon Transverse	1	0.048	1.7
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.7
GTEx	Esophagus Mucosa	3	0.090	1.7
GTEx	Esophagus Muscularis	2	0.062	1.7
GTEx	Heart Atrial Appendage	0	0.000	1.7
GTEx	Liver	2	0.279	1.7
GTEx	Ovary	0	0.000	1.7
GTEx	Pancreas	1	0.061	1.7
GTEx	Pituitary	0	0.000	1.7
GTEx	Prostate	0	0.000	1.7
GTEx	Skin Not Sun Exposed Suprapubic	2	0.081	1.7
GTEx	Skin Sun Exposed Lower leg	4	0.110	1.7
GTEx	Small Intestine Terminal Ileum	0	0.000	1.7
GTEx	Testis	1	0.032	1.7
GTEx	Thyroid	2	0.050	1.7
GTEx	Whole Blood	2	0.100	1.7
ROSMAP	Brain Pre-frontal Cortex	3	0.068	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	6	0.291	1.7
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.7
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	2	0.049	1.7
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	3	0.102	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.120	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	1	0.060	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.7
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.7
GTEx	Artery Coronary	0	0.000	1.6
GTEx	Brain Caudate basal ganglia	0	0.000	1.6
GTEx	Brain Hippocampus	0	0.000	1.6
GTEx	Brain Hypothalamus	0	0.000	1.6
GTEx	Brain Putamen basal ganglia	1	0.160	1.6
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.6
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.6
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.6
GTEx	Colon Sigmoid	1	0.068	1.6
GTEx	Heart Left Ventricle	0	0.000	1.6
GTEx	Nerve Tibial	1	0.023	1.6
GTEx	Spleen	0	0.000	1.6
GTEx	Uterus	0	0.000	1.6
METSIM	Adipose	2	0.043	1.6
NTR	Blood	0	0.000	1.6
YFS	Blood	6	0.130	1.6
CommonMind	Brain Pre-frontal Cortex	8	0.149	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	8	0.182	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	3	0.110	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	2	0.046	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	5	0.108	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	4	0.078	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.5